Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 28, 2022 at 08:12 pm IST
Share
Guangzhou LBP Medicine Science & Technology Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 120.09 million compared to CNY 99.51 million a year ago. Revenue was CNY 120.09 million compared to CNY 99.51 million a year ago. Net income was CNY 19.62 million compared to CNY 26.66 million a year ago. Basic earnings per share from continuing operations was CNY 0.21 compared to CNY 0.29 a year ago. Diluted earnings per share from continuing operations was CNY 0.21 compared to CNY 0.29 a year ago.
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Companyâs main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.